Initial Report: Personalized Circulating Tumor DNA and Survival in Patients with Resectable Pancreatic Cancer
Austin M. Eckhoff,Elishama Kanu,Ashley Fletcher,Matthew Bao,Vasily N. Aushev,Erik Spickard,Daniel P. Nussbaum,Peter J. Allen
DOI: https://doi.org/10.1245/s10434-023-14751-2
IF: 4.339
2024-01-03
Annals of Surgical Oncology
Abstract:BackgroundPancreatic adenocarcinoma (PDAC) is highly lethal with up to 80% of resected patients experiencing disease recurrence within 2 years (Watanabe, Nakamura, Kimura et al in Int J Mol Sci 23(19):11521, 2022). Cross-sectional imaging and serum tumor markers are used for monitoring post-operative recurrence; however, both have significant limitations (Edland, Tjensvoll, Oltedal et al in Mol Oncol 17:1857–1870, 2023). Circulating tumor DNA (ctDNA) has emerged as a valuable prognostic tool to measure molecular residual disease (MRD) and predict recurrence in solid tumors (Watanabe, Nakamura, Kimura et al in Int J Mol Sci 23(19):11521, 2022). In this study, we evaluated the feasibility of a personalized, tumor-informed ctDNA assay to detect recurrence prior to standard surveillance tools in patients with PDAC.Patients and MethodsAfter Institutional Review Board (IRB) approval (Pro00106870), we assessed serial ctDNA measurements (n = 177) from 35 patients with resectable PDAC treated by either upfront resection or neoadjuvant chemotherapy. Plasma samples (median 4 ml, interquartile range 0.6–5.9 ml) were isolated from blood collected in EDTA tubes and banked at diagnosis, during neoadjuvant therapy if applicable, on the day of surgery, and every 2–3 months postoperatively. A tumor-informed assay (Signatera™, Natera, Inc.) that tracks up to 16 individual-specific, somatic single nucleotide variants in the corresponding patient’s plasma samples were used for ctDNA detection. Survival was calculated using Kaplan–Meier curves, and significance was determined with the log-rank test.ResultsPersonalized ctDNA assays were successfully designed for all patients (with 32/35 patients having 16-plex assays). Median follow-up from initial treatment was 13 months (range 1–26 months; Table 1). ctDNA-positivity at any time point was observed in 40% (14/35) of patients. During the follow-up period, 18 patients (51%) developed radiographic evidence of recurrence after a median of 9 months of follow-up (range 1–26 months). At the time of radiographic recurrence, 50% (9/18) of patients were ctDNA-positive. During the immediate postoperative period (up to 9 weeks post-surgery), RFS and OS were significantly inferior in patients who were ctDNA-positive versus ctDNA-negative (RFS 97 versus 297 days, p < 0.001; OS 110 versus 381 days, p < 0.001; Fig. 1).Table 1Cohort demographics (N = 35); patient demographics, tumor characteristics, and survivalGender (%)Female 17 (49%)Male 18 (51%)Median age (IQR)70 years (65–75 years)Neoadjuvant treatment (%)11 (31%)Median sample plasma volume (IQR)4.0 mL (0.6–5.9 mL)Median follow-up (range)13 months (1–26 months)Median initial CA 19-9 in U/mL (IQR)56 (18–160)Median tumor size in cm (IQR)2.5 (1.8–3.3)Median number of positive lymph nodes (IQR)1 (0–3)Median recurrence-free survival9.4 monthsMedian overall survivalN/A (not reached)Fig. 1a Overview plot showing longitudinal ctDNA status, treatment regimen, and clinical outcomes for each patient (N = 35); median follow-up from the start of the neoadjuvant therapy/surgery was 13 months (range 1–26 months); ctDNA at any time point was 40% (14/35); out of the 35 patients, 18 (51%) developed radiographic evidence of recurrence (median RFS: 9 months), and of these 18 patients with clinical recurrence, 9 (50%) were ctDNA-positive and the remaining ctDNA-negative; notably, all ctDNA-negative patients with recurrence had suboptimal plasma volume available for ctDNA analysis; b, c Kaplan–Meier estimates representing the association of ctDNA status with (b) RFS and (c) OS, at MRD time point (9 weeks post-surgery)DiscussionOur study demonstrates the feasibility of tumor-informed ctDNA-based MRD testing in resectable PDAC and shows that MRD detected by ctDNA within the immediate postoperative period portends a dismal prognosis. This information is valuable for both patients and clinicians in setting prognostic expectations.
oncology,surgery